keyword
MENU ▼
Read by QxMD icon Read
search

Hepatitis c genotype 4

keyword
https://www.readbyqxmd.com/read/29150360/changes-in-the-epidemiology-and-distribution-of-the-hepatitis-c-virus-genotypes-in-north-eastern-spain-over-the-last-35-years
#1
Doroteo Acero Fernández, María José Ferri Iglesias, María Buxó Pujolràs, Carmen López Nuñez, Isabel Serra Matamala, Xavier Queralt Molés, Xavier Aldeguer Manté
BACKGROUND: Genotypic distribution and epidemiology of HCV infection in Western Europe countries has changed over the last decades. AIM: To establish the local genotypic profile and characterize the associated demographic variables. MATERIAL AND METHOD: All the genotyping from 1988 to 2015 were considered. Associated demographic variables were included in logistic regression models. Genotyping was carried out with updated commercial kits. RESULTS: Genotype 1b was the most prevalent (42...
November 14, 2017: Gastroenterología y Hepatología
https://www.readbyqxmd.com/read/29149205/kir-content-genotypes-associate-with-carriage-of-hepatitis-b-surface-antigen-e-antigen-and-hbv-viral-load-in-gambians
#2
Louis-Marie Yindom, Maimuna Mendy, Christopher Bodimeade, Caroline Chambion, Peter Aka, Hilton C Whittle, Sarah L Rowland-Jones, Robert Walton
BACKGROUND: Hepatocellular carcinoma (HCC) causes over 800,000 deaths worldwide annually, mainly in low income countries, and incidence is rising rapidly in the developed world with the spread of hepatitis B (HBV) and C (HCV) viruses. Natural Killer (NK) cells protect against viral infections and tumours by killing abnormal cells recognised by Killer-cell Immunoglobulin-like Receptors (KIR). Thus genes and haplotypes encoding these receptors may be important in determining both outcome of initial hepatitis infection and subsequent chronic liver disease and tumour formation...
2017: PloS One
https://www.readbyqxmd.com/read/29147645/real-world-cure-rates-for-hepatitis-c-virus-treatments-that-include-simeprevir-and-or-sofosbuvir-are-comparable-to-clinical-trial-results
#3
Kian Bichoupan, Neeta Tandon, James F Crismale, Joshua Hartman, David Del Bello, Neal Patel, Sweta Chekuri, Alyson Harty, Michel Ng, Keith M Sigel, Meena B Bansal, Priya Grewal, Charissa Y Chang, Jennifer Leong, Gene Y Im, Lawrence U Liu, Joseph A Odin, Nancy Bach, Scott L Friedman, Thomas D Schiano, Ponni V Perumalswami, Douglas T Dieterich, Andrea D Branch
AIM: To assess the real-world effectiveness and cost of simeprevir (SMV), and/or sofosbuvir (SOF)-based therapy for chronic hepatitis C virus (HCV) infection. METHODS: The real-world performance of patients treated with SMV/SOF ± ribavirin (RBV), SOF/RBV, and SOF/RBV with pegylated-interferon (PEG) were analyzed in a consecutive series of 508 patients with chronic HCV infection treated at a single academic medical center. Patients with genotypes 1 through 4 were included...
November 12, 2017: World Journal of Virology
https://www.readbyqxmd.com/read/29145802/effectiveness-of-current-and-future-regimens-for-treating-genotype-3-hepatitis-c-virus-infection-a-large-scale-systematic-review
#4
Hosnieh Fathi, Andrew Clark, Nathan R Hill, Geoffrey Dusheiko
BACKGROUND: Six distinct genetic variants (genotypes 1 - 6) of hepatitis C virus (HCV) exist globally. Certain genotypes are more prevalent in particular countries or regions than in others but, globally, genotype 3 (GT3) is the second most common. Patients infected with HCV GT1, 2, 4, 5 or 6 recover to a greater extent, as measured by sustained virological response (SVR), following treatment with regimens based on direct-acting antivirals (DAAs) than after treatment with older regimens based on pegylated interferon (Peg-IFN)...
November 16, 2017: BMC Infectious Diseases
https://www.readbyqxmd.com/read/29143142/prevalence-of-ns5b-resistance-associated-variants-in-treatment-na%C3%A3-ve-asian-patients-with-chronic-hepatitis-c
#5
Song Yang, Huichun Xing, Shenghu Feng, Wei Ju, Shunai Liu, Xiaomei Wang, Weini Ou, Jun Cheng, Calvin Q Pan
There is little information on the association between baseline non-structural protein (NS) 5b resistance-associated variants (RAVs) and treatment failure in hepatitis C patients. This study examined the frequencies of natural hepatitis C virus (HCV) NS5B resistance-associated variants (RAVs) in an Asian cohort. Samples from Asian HCV patients enrolled between October 2009 and September 2014 were analyzed for NS5B RAVs within the region from amino acid 230 to 371. Serum samples were tested by PCR genotyping, with sequence alignment performed using the neighbor-joining method...
November 15, 2017: Archives of Virology
https://www.readbyqxmd.com/read/29141246/evaluation-of-temporal-virological-responses-to-interferon-%C3%AE-2b-plus-ribavirin-among-genotype-3a-hepatitis-c-virus-infected-patients
#6
Abida Raza, Muhammad Ovais, Hafsa Aziz, Asim Anwar, Javaid Irfan, Irshad Ahmad, Muhammad Mukhtar
OBJECTIVES: The present study aimed to examine the impact of rapid virological response (RVR) and early virological response (EVR) on sustained virological response (SVR) in chronic hepatitis C genotype 3a individuals. METHODS: The patients were given antiviral therapy with IFN-α-2b, 3 million units 3 times a week and 800-1,200 mg of ribavirin daily adjusted to the patient's body weight (<60 kg 800 mg day-1, and >60 kg 1,200 day-1). The patients received this combination therapy for 24 weeks...
November 16, 2017: Intervirology
https://www.readbyqxmd.com/read/29138492/the-antigenic-variability-of-hcv-in-viral-hla-ag-binding-is-related-to-the-activation-of-the-host-immune-response
#7
P Muñoz de Rueda, S M Jiménez-Ruiz, R Quiles, E J Pavón-Castillero, J A Muñoz-Gámez, J Casado, A Gila, A Ruiz-Extremera, J Salmerón
Our previous data show that hepatitis C virus (HCV) genotype 1 patients expressing the HLA-DQB1 * 0301 allele have a combined response probability of 69%, while the remaining 31% do not respond, probably because the HCV immunodominant epitope (IE) against the DQB1 * 0301 allele is mutated. HCV IE (region sequenced in NS3 is a region encoding aa 1253-1272) from 37 patients (21 Sustained Virological Response, SVR; 16 non-SVR) HLA-DQB1 * 0301+, were analysed by pyrosequencing. In vitro cultures were also determined by CD4+ proliferation, using non-mutated IE (wild-type synthetic peptide) and synthetic mutated peptide...
November 14, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29135773/tree-based-claims-algorithm-for-measuring-pretreatment-quality-of-care-in-medicare-disabled-hepatitis-c-patients
#8
Viktor V Chirikov, Fadia T Shaya, Ebere Onukwugha, C Daniel Mullins, Susan dosReis, Charles D Howell
BACKGROUND: To help broaden the use of machine-learning approaches in health services research, we provide an easy-to-follow framework on the implementation of random forests and apply it to identify quality of care (QC) patterns correlated with treatment receipt among Medicare disabled patients with hepatitis C virus (HCV). METHODS: Using Medicare claims 2006-2009, we identified 1936 patients with 6 months continuous enrollment before HCV diagnosis. We ran a random forest on 14 pretreatment QC indicators, extracted the forest's representative tree, and aggregated its terminal nodes into 4 QC groups predictive of treatment...
December 2017: Medical Care
https://www.readbyqxmd.com/read/29135370/pharmacokinetics-based-adjusted-versus-standard-dose-of-ribavirin-does-not-improve-virologic-response-rates-in-chronic-hepatitis-c-genotype-4-patients-a-randomized-controlled-trial
#9
Ibrahim H Altraif, Faisal Sanai, Mohammed A Babatin, Abduljaleel A Alalwan, Ayman A Abdo, Waleed Alhamoudi, Musthafa Peedikayil, Hamdan Alghamdi, Fahad Alsohaibani, Khalid A Alswat, Shazia Murtaza, Abdullah Alghamdi, Sara Altraif, Abdulrahman Aljumah, Fayaz A Handoo, Abdulkareem M AlBekairy, Hamad I Al-Ashgar, Mohammed Alquaiz, Mohammed A Alblawi, Waleed AlTamimi, Véronique Loustaud-Ratti, Pierre Marquett
Optimal doses of Ribavirin (RBV) for hepatitis C virus (HCV) treatment are not known. To assess the safety and efficacy of PegIFNalfa-2a in combination with an adjusted (ADJ) RBV dose based on early pharmacokinetics versus a fixed standard (STD) dose of RBV in chronic HCV genotype (GT) 4-naive patients in a randomized trial. One hundred eighty-one patients were randomized. The baseline variables were similar in both arms and females were 50.3% of the patients, 76.5% had minimal-moderate fibrosis (F0-2). Sustained virologic response (SVR) was achieved in 99 (54...
November 2017: Journal of Interferon & Cytokine Research
https://www.readbyqxmd.com/read/29135030/hepatitis-c-virus-clearance-in-older-adults
#10
Antonio Massimo Ippolito, Angelo Iacobellis, Michele Milella, Fabio Conti, Vincenzo Messina, Maria Rosa Valvano, Grazia Anna Niro, Filomena Morisco, Michele Barone, Antonio Patrizio Termite, Giuseppina Brancaccio, Angelo Andriulli
OBJECTIVES: To determine whether older adults with the hepatitis C virus (HCV) achieve a sustained viral response (SVR) after treatment with direct-acting antiviral therapy. PARTICIPANTS: Individuals aged 80 and older with chronic HCV infection (N = 253; n = 213 with cirrhosis, n = 40 with advanced fibrosis). MEASUREMENTS: We investigated the efficacy, safety, and global clinical effect of treatment with different combinations of direct antiviral agents (DAAs)...
November 14, 2017: Journal of the American Geriatrics Society
https://www.readbyqxmd.com/read/29133129/hbsag-mrna-degradation-induced-by-dihydroquinolizinone-molecule-depends-on-hbv-posttranscriptional-regulatory-element
#11
Tianlun Zhou, Timothy Block, Fei Liu, Andrew S Kondratowicz, Liren Sun, Siddhartha Rawat, Jeffrey Branson, Fang Guo, Hongyan Liang, Lauren Bailey, Chris Moore, Xiaohe Wang, Andy Cuconatti, Min Gao, Amy C H Lee, Troy Harasym, Tim Chiu, Dimitar Gotchev, Bruce Dorsey, Rene Rijnbrand, Michael J Sofia
In pursuit of novel therapeutics targeting the hepatitis B virus (HBV) infection, we evaluated a dihydroquinolizinone compound (DHQ-1) that possessed nanomolar activities against the production of virion and surface protein (HBsAg) in tissue culture. This compound also showed broad HBV genotype coverage and was inactive against a panel of DNA and RNA viruses of other species. Oral administration of DHQ-1 in the AAV-HBV mouse model resulted in a strong reduction of serum HBsAg as soon as 4 days following the commencement of treatment...
November 10, 2017: Antiviral Research
https://www.readbyqxmd.com/read/29115151/sofosbuvir-velpatasvir-voxilaprevir-a-pan-genotypic-direct-acting-antiviral-combination-for-hepatitis-c
#12
Elias B Chahine, Denise Kelley, Lindsey M Childs-Kean
OBJECTIVES: To review the efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C virus (HCV) infection. DATA SOURCES: A literature search through PubMed was conducted (August 2010 to August 2017) using the terms GS-9857, voxilaprevir, and NS3/4A protease inhibitor. STUDY SELECTION/DATA EXTRACTION: Studies of sofosbuvir/velpatasvir/voxilaprevir were identified. DATA SYNTHESIS: Sofosbuvir/velpatasvir/voxilaprevir is indicated for adult patients with chronic HCV without cirrhosis or with compensated cirrhosis who have (1) genotype 1 through 6 and have previously been treated with an NS5A inhibitor or (2) genotype 1a or 3 and have previously been treated with sofosbuvir without an NS5A inhibitor...
November 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/29112765/epidemiology-and-risk-factors-for-hepatitis-c-virus-genotypes-in-a-high-prevalence-region-in-italy
#13
Antonio Riccardo Buonomo, Riccardo Scotto, Biagio Pinchera, Nicola Coppola, Caterina Monari, Margherita Macera, Guglielmo Borgia, Ivan Gentile
Hepatitis C virus (HCV) is globally widespread. Southern Italy is a high prevalence region where the distribution of the HCV genotypes (GTs) is changing. Intravenous drug abuse is the only risk factor associated with a specific HCV GT (GT3). The aim of this study was to evaluate the distribution and the risk factors for specific HCV GTs. A total of 682 patients with measurable serum HCV-RNA were enrolled between January and March 2017. We recorded clinical information and the presence of risk factors for HCV...
November 7, 2017: New Microbiologica
https://www.readbyqxmd.com/read/29111616/daclatasvir-and-asunaprevir-treatment-in-patients-infected-by-genotype-1b-of-hepatitis-c-virus-with-no-or-subtle-resistant-associated-substitutions-ras-in-ns5a-y93
#14
Masatoshi Ishigami, Kazuhiko Hayashi, Takashi Honda, Teiji Kuzuya, Yoji Ishizu, Tetsuya Ishikawa, Isao Nakano, Fumihiro Urano, Takashi Kumada, Kentaro Yoshioka, Yoshiki Hirooka, Hidemi Goto
(Backgrounds and Aims) In this study, we investigated the real-world data of the first approved interferon free regimen in Japan; daclatasvir and asunaprevir (DCV+ASV) in chronic hepatitis C patients infected HCV genotype 1b with no or subtle amount of baseline resistant associated substitutions (RAS). (Patients and Methods) Among 924 patients registered in our multicenter study, 750 patients that were proven not to be infected with NS5A-Y93H resistant associated substitutions (RAS) by direct sequencing and to have no or subtle amount (less than 20%) of NS5A-Y93H RAS by probe assays (Cycleave or PCR invader assay) were included in this study...
November 7, 2017: Journal of Medical Virology
https://www.readbyqxmd.com/read/29108017/assessing-risk-of-fibrosis-progression-and-liver-related-clinical-outcomes-among-patients-with-both-early-stage-and-advanced-chronic-hepatitis-c
#15
Monica A Konerman, Dongxia Lu, Yiwei Zhang, Mary Thomson, Ji Zhu, Aashesh Verma, Boang Liu, Nizar Talaat, Ulysses Balis, Peter D R Higgins, Anna S F Lok, Akbar K Waljee
OBJECTIVE: Assessing risk of adverse outcomes among patients with chronic liver disease has been challenging due to non-linear disease progression. We previously developed accurate prediction models for fibrosis progression and clinical outcomes among patients with advanced chronic hepatitis C (CHC). The primary aim of this study was to validate fibrosis progression and clinical outcomes models among a heterogeneous patient cohort. DESIGN: Adults with CHC with ≥3 years follow-up and without hepatic decompensation, hepatocellular carcinoma (HCC), liver transplant (LT), HBV or HIV co-infection at presentation were analyzed (N = 1007)...
2017: PloS One
https://www.readbyqxmd.com/read/29105285/historical-epidemiology-of-hepatitis-c-virus-in-select-countries-volume-4
#16
A Maaroufi, A Vince, S M Himatt, R Mohamed, J Fung, O Opare-Sem, A Workneh, R Njouom, I Al Ghazzawi, M Abdulla, K S Kaliaskarova, S Owusu-Ofori, M K Abdelmageed, D Adda, O Akin, A Al Baqali, N Al Dweik, K Al Ejji, S Al Kaabi, K Al Naamani, J Al Qamish, M Al Sadadi, J Al Salman, M AlBadri, S A Al-Busafi, H E Al-Romaihi, W Ampofo, K Antonov, C Anyaike, F Arome, A Bane, S Blach, M M Borodo, S M Brandon, B Bright, M T Butt, I Cardenas, H L Y Chan, C J Chen, D S Chen, P J Chen, R N Chien, W L Chuang, D Cuellar, M Derbala, A A Elbardiny, C Estes, E Farag, I Gamkrelidze, V Garcia, J Genov, Z Ghandour, M Ghuloom, B Gomez, J Gunter, J Habeeb, O Hajelssedig, W Hamoudi, I Hrstic, C C Hu, C F Huang, Y T Hui, R Jahis, D Jelev, A K John, Y Kamel, J H Kao, J Khamis, H Khattabi, I Khoudri, A Konysbekova, I Kotzev, M S Lai, W C Lao, J Layden, M H Lee, O Lesi, M Li, A Lo, C K Loo, B Lukšić, A O Malu, L Mateva, R Mitova, M Morović, K Murphy, B Mustapha, H Nde, A Nersesov, E Ngige, O Njoya, D Nonković, S Obekpa, S Oguche, E E Okolo, O Omede, C Omuemu, P Ondoa, R O Phillips, Y N Prokopenko, H Razavi, D Razavi-Shearer, B Redae, T Reic, T Rinke de Wit, C Rios, S Robbins, L R Roberts, S J Sanad, J D Schmelzer, M Sharma, M Simonova, T H Su, K Sultan, S S Tan, K Tchernev, O T Y Tsang, S Tsang, C Tzeuton, S Ugoeze, B Uzochukwu, R Vi, H U Wani, V W S Wong, R Yacoub, K I Yesmembetov, M Youbi, M F Yuen, K Razavi-Shearer
Due to the introduction of newer, more efficacious treatment options, there is a pressing need for policy makers and public health officials to develop or adapt national hepatitis C virus (HCV) control strategies to the changing epidemiological landscape. To do so, detailed, country-specific data are needed to characterize the burden of chronic HCV infection. In this study of 17 countries, a literature review of published and unpublished data on HCV prevalence, viraemia, genotype, age and gender distribution, liver transplants and diagnosis and treatment rates was conducted, and inputs were validated by expert consensus in each country...
October 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29104462/association-of-ifnl3-genotype-with-hepatic-steatosis-in-chronic-hepatitis-c-patients-treated-with-peginterferon-and-ribavirin-combination-therapy
#17
Shingo Nakamoto, Fumio Imazeki, Tatsuo Kanda, Shuang Wu, Masato Nakamura, Shin Yasui, Akinobu Tawada, Rintaro Mikata, Tetsuhiro Chiba, Makoto Arai, Osamu Yokosuka, Hiroshi Shirasawa
BACKGROUND: Genetic variation near the interferon lambda 3 (IFNL3) is known to be associated with response to pegylated interferon (pegIFN) and ribavirin combination therapy in patients with chronic hepatitis C virus (HCV) infection which is often accompanied by hepatic steatosis. AIMS: We examined whether this genetic variation is associated with host lipids and treatment response. METHODS: A total of 101 Japanese patients who had underwent liver biopsy before treatment with pegIFN and ribavirin for HCV genotype 1b infection were retrospectively analyzed for association between IFNL3 genotypes (rs8099917) and clinical factors including histopathological features of the liver...
2017: International Journal of Medical Sciences
https://www.readbyqxmd.com/read/29096662/hepatitis-c-virus-genotypes-in-saudi-arabia-a-future-prediction-and-laboratory-profile
#18
Amen Bawazir, Fahad AlGusheri, Hoda Jradi, Mohammed AlBalwi, Abdel-Galil Abdel-Gader
BACKGROUND: Hepatitis C virus (HCV) genotypes and subtypes are considered an important tool for epidemiological and clinical studies and valuable markers for disease progression and response to antiviral therapy. The aim of this study was to identify the prevalence of HCV genotypes and their relation to socio-demographic factors particularly age and sex, various biochemical profiles and viral load. METHODS: The records (630) of Saudi patients positive for HCV (2007-2011) reported in the system of the Molecular Pathology Laboratory at a tertiary reference hospital in Riyadh, Saudi Arabia were analyzed...
November 2, 2017: Virology Journal
https://www.readbyqxmd.com/read/29091342/ledipasvir-sofosbuvir-for-treatment-of-hepatitis-c-virus-in-sofosbuvir-experienced-ns5a-treatment-naive-patients-findings-from-two-randomized-trials
#19
Edward Tam, Anne F Luetkemeyer, Parvez S Mantry, Sanjaya K Satapathy, Peter Ghali, Minhee Kang, Richard Haubrich, Xianlin Shen, Liyun Ni, Gregory Camus, Amanda Copans, Lorenzo Rossaro, Bill Guyer, Robert S Brown
BACKGROUND & AIMS: We report data from two similarly designed studies that evaluated the efficacy, safety, and optimal duration of ledipasvir/sofosbuvir (LDV/SOF) ± ribavirin (RBV) for retreatment of chronic hepatitis C virus (HCV) in individuals who failed to achieve sustained virologic response (SVR) with prior SOF-based, non-NS5A inhibitor-containing regimens. METHODS: The RESCUE study enrolled HCV mono-infected adults with genotype 1 or 4. Non-cirrhotic participants were randomized to 12 weeks of LDV/SOF or LDV/SOF+RBV...
November 1, 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/29090229/ctla-4-gene-haplotypes-and-the-risk-of-chronic-hepatitis-c-infection-a-case-control-study
#20
Samaneh Sepahi, Alireza Pasdar, Sina Gerayli, Sina Rostami, Aida Gholoobi, Zahra Meshkat
BACKGROUND: The prevalence of hepatitis C virus (HCV) infection is increasing worldwide. Cytotoxic Tlymphocyte-associated protein 4 (CTLA-4) may play a role in the intensity of the disease. The aim of this study was to evaluate the association between genetic variants of the CTLA-4 and HCV infection. METHODS: Restriction fragment length polymorphism-polymerase chain reaction (RFLP-PCR) was performed as the genotyping assay at four different positions (+49 A>G, -318 C>T, -1722 T>C, and - 1661 A>G)...
October 2017: Reports of Biochemistry & Molecular Biology
keyword
keyword
86765
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"